Skip to main content
Livermore
Livermore
ZHEN

Silverarc Capital Management, LLC

SEC CIK
0001816307
Latest filing
Aug 13, 2026

The latest 13F from Silverarc Capital Management, LLC covers Q2 2026 (filed Aug 13, 2026): 65 long positions worth $898.5M. The top 10 holdings make up 45.3% of the portfolio, and the largest is Ascendis Pharma A/S (ASND) at 6.1%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
19
Est. +$157.8M
Added
17
Est. +$107.0M
Reduced
27
Est. −$166.6M
Sold out
21
Est. −$184.5M

Top 5 holdings

Share of this quarter's portfolio value

  1. ASNDAscendis Pharma A/S
    6.1%$55.0MHistory
  2. CELCCelcuity Inc.
    5.8%$52.4MHistory
  3. COGTCogent Biosciences, Inc.
    5.5%$49.6MHistory
  4. URGNUroGen Pharma Ltd.
    5.3%$47.9MHistory
  5. IMNMImmunome Inc.
    4.8%$42.7MHistory

Share of portfolio

Top 5 holdings and the other 60 positions, by share of portfolio value

  1. ASND6.1%
  2. CELC5.8%
  3. COGT5.5%
  4. URGN5.3%
  5. IMNM4.8%
  6. Other 60 positions72.4%

Biggest buys

New and added positions, by estimated amount bought

  1. ELVNEnliven Therapeutics, Inc.
    +$24.8MNewHistory
  2. SGMTSagimet Biosciences Inc.
    +$22.6MNewHistory
  3. ASNDAscendis Pharma A/S
    +$21.8MAddedHistory
  4. ORKAOruka Therapeutics, Inc.
    +$19.2MAddedHistory
  5. DFTXDefinium Therapeutics, Inc.
    +$18.8MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ORKAOruka Therapeutics, Inc.
    +2.86 pp0.9% → 3.7%History
  2. ELVNEnliven Therapeutics, Inc.
    +2.76 pp0.0% → 2.8%History
  3. ASNDAscendis Pharma A/S
    +2.76 pp3.4% → 6.1%History
  4. SGMTSagimet Biosciences Inc.
    +2.52 pp0.0% → 2.5%History
  5. DFTXDefinium Therapeutics, Inc.
    +2.09 pp0.0% → 2.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. KALVKalVista Pharmaceuticals, Inc.
    −$57.9MSold outHistory
  2. NUVLNuvalent, Inc.
    −$36.4MSold outHistory
  3. DNTHDianthus Therapeutics, Inc.
    −$25.8MReducedHistory
  4. GLUEMonte Rosa Therapeutics, Inc.
    −$21.6MReducedHistory
  5. CNTACentessa Pharmaceuticals plc
    −$18.5MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. KALVKalVista Pharmaceuticals, Inc.
    −6.82 pp6.8% → 0.0%History
  2. NUVLNuvalent, Inc.
    −4.28 pp4.3% → 0.0%History
  3. DNTHDianthus Therapeutics, Inc.
    −2.24 pp6.5% → 4.2%History
  4. CNTACentessa Pharmaceuticals plc
    −2.18 pp2.2% → 0.0%History
  5. KODKodiak Sciences Inc.
    −2.09 pp4.5% → 2.4%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$898.5M
+$49.9M (+5.9%) vs. prior quarter
Positions
65
−2 vs. prior quarter
Top 10 concentration
45.3%
Top 10 as share of value
Turnover
30.3%
Q2 2026, one quarter
Average holding period
5.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $898.5M (Q2 2026)

Q1 2021: $178.5MQ2 2021: $190.0MQ3 2021: $172.6MQ4 2021: $223.2MQ1 2022: $184.2MQ2 2022: $213.4MQ3 2022: $235.8MQ4 2022: $290.5MQ1 2023: $222.5MQ2 2023: $296.2MQ3 2023: $268.4MQ4 2023: $324.2MQ1 2024: $356.6MQ2 2024: $405.1MQ3 2024: $443.8MQ4 2024: $447.2MQ1 2025: $478.6MQ2 2025: $488.6MQ3 2025: $690.7MQ4 2025: $691.1MQ1 2026: $848.6MQ2 2026: $898.5M
Q1 2021Q2 2026
13F filings of Silverarc Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 13, 202665$898.5MASNDCELCCOGTvs. Q1 2026SEC
Q1 2026May 14, 202667$848.6MKALVDNTHCOGTvs. Q4 2025SEC
Q4 2025Feb 12, 202664$691.1MABVXCOGTURGNvs. Q3 2025SEC
Q3 2025Nov 12, 202573$690.7MABVXRYTMAvidity Biosciences, Inc.vs. Q2 2025SEC
Q2 2025Aug 14, 202557$488.6MMRUSAKROVRNAvs. Q1 2025SEC
Q1 2025May 14, 202567$478.6MVRNAMRUSNUVLvs. Q4 2024SEC
Q4 2024Feb 14, 202558$447.2MNUVLMRUSINSMvs. Q3 2024SEC
Q3 2024Nov 14, 202468$443.8MNUVLMRUSINSMvs. Q2 2024SEC
Q2 2024Aug 14, 202466$405.1MMRUSNUVLAvidity Biosciences, Inc.vs. Q1 2024SEC
Q1 2024May 15, 202473$356.6MMRUSSLDBMORFvs. Q4 2023SEC
Q4 2023Feb 14, 202464$324.2MMRUSMRSNMORFvs. Q3 2023SEC
Q3 2023Nov 13, 202368$268.4MIMGNMORFMRUSvs. Q2 2023SEC
Q2 2023Aug 14, 202377$296.2MIMGNMRUSMORFvs. Q1 2023SEC
Q1 2023May 15, 202367$222.5MMRUSMGNXVRAYvs. Q4 2022SEC
Q4 2022Feb 14, 202381$290.5MMDGLBellus Health Inc NewPSTXvs. Q3 2022SEC
Q3 2022Oct 28, 202269$235.8MBellus Health Inc NewVCYTAKROvs. Q2 2022SEC
Q2 2022Jul 25, 202259$213.4MITCIBellus Health Inc NewVCYTvs. Q1 2022SEC
Q1 2022May 13, 202265$184.2MITCISRRAVCYTvs. Q4 2021SEC
Q4 2021Feb 14, 202268$223.2MIMGNBHVNITCIvs. Q3 2021SEC
Q3 2021Nov 15, 202179$172.6MBHVNVCYTMRTXvs. Q2 2021SEC
Q2 2021Aug 16, 202191$190.0MDRNAMRUSMRTXvs. Q1 2021SEC
Q1 2021May 18, 202188$178.5MACRSCRISVCEL–SEC

13D and 13G filings

Companies where Silverarc Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

4 companies, largest stake first.

Companies where Silverarc Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
IBIOiBio, Inc.13G9.99%2.18M sharesNewNov 14, 20251 filingNov 14, 2025SEC
CLRBCellectar Biosciences, Inc.13G9.99%851.3K sharesNewAug 14, 20261 filingAug 14, 2026SEC
HLXCHelix Acquisition Corp. III13G6.80%1.21M sharesNewMay 13, 20261 filingMay 13, 2026SEC
KALVKalVista Pharmaceuticals, Inc.13G5.60%2.88M sharesNewMay 13, 20261 filingMay 13, 2026SEC

Latest filings

31 filings on file made by Silverarc Capital Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Silverarc Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
TELATELA Bio, Inc.Aug 14, 202612:53 PM ET13G/A4.80%2.14M shares0.00 ppfrom 4.80%Below 5%Jun 30, 2026SEC
KALVKalVista Pharmaceuticals, Inc.Aug 14, 202612:48 PM ET13G/A0.00%0 shares0.00 ppfrom 0.00%Below 5%Jun 30, 2026SEC
ELUTElutia Inc.Aug 14, 202612:46 PM ET13G/A4.90%2.19M shares0.00 ppfrom 4.90%Below 5%Jun 30, 2026SEC
CLRBCellectar Biosciences, Inc.Aug 14, 202612:11 PM ET13G9.99%851.3K sharesNewJun 30, 2026SEC
TELATELA Bio, Inc.Aug 11, 202610:44 AM ET13G4.80%2.14M shares−3.00 ppfrom 7.80%Below 5%Jun 30, 2026SEC
KALVKalVista Pharmaceuticals, Inc.Aug 11, 202610:42 AM ET13G0.00%0 sharesNewBelow 5%Jun 30, 2026SEC
ELUTElutia Inc.Aug 11, 202610:37 AM ET13G4.90%2.19M shares−1.00 ppfrom 5.90%Below 5%Jun 30, 2026SEC
NXTCNextCure, Inc.May 13, 20264:42 PM ET13G/A4.90%176.1K shares−0.12 ppfrom 5.02%Below 5%Mar 31, 2026SEC
KALVKalVista Pharmaceuticals, Inc.May 13, 20264:40 PM ET13G5.60%2.88M sharesNewMar 31, 2026SEC
HLXCHelix Acquisition Corp. IIIMay 13, 20264:35 PM ET13G6.80%1.21M sharesNewMar 31, 2026SEC
GUTSFractyl Health, Inc.May 13, 20264:20 PM ET13G/A2.30%3.61M shares−5.72 ppfrom 8.02%Below 5%Mar 31, 2026SEC
NXTCNextCure, Inc.Feb 12, 202612:05 PM ET13G5.02%176.1K sharesNewDec 31, 2025SEC
AVTXAvalo Therapeutics, Inc.Feb 10, 202611:36 AM ET13G2.83%524.4K shares−2.65 ppfrom 5.48%Below 5%Dec 31, 2025SEC
IBIOiBio, Inc.Nov 14, 20251:11 PM ET13G9.99%2.18M sharesNewSep 30, 2025SEC
GUTSFractyl Health, Inc.Nov 14, 202512:47 PM ET13G8.02%10.6M sharesNewSep 30, 2025SEC
AVTXAvalo Therapeutics, Inc.Nov 14, 202512:39 PM ET13G5.48%720.9K sharesNewSep 30, 2025SEC
TELATELA Bio, Inc.Feb 12, 20253:54 PM ET13G7.80%3.07M sharesNewDec 31, 2024SEC
MTEMMolecular Templates, Inc.Feb 12, 20253:53 PM ET13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
ELUTElutia Inc.Feb 12, 20253:44 PM ET13G/A5.90%1.78M shares–Dec 31, 2024SEC
ELUTElutia Inc.Oct 15, 202413GOld format–New–SEC